## **Core Concept**
The question describes a patient with a bone lesion that presents with severe pain relieved by aspirin and shows a lucent lesion surrounded by marked reactive sclerosis on plain film. This scenario suggests a bone tumor or a bone-related condition that has an inflammatory component.
## **Why the Correct Answer is Right**
The correct answer, **. Osteoid Osteoma**, is a benign bone tumor that typically presents with nocturnal pain that is relieved by nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin. The radiographic appearance of a small, lucent nidus surrounded by a zone of reactive sclerosis is characteristic of osteoid osteoma. This matches the description provided in the question.
## **Why Each Wrong Option is Incorrect**
- **Option A:** Giant Cell Tumor - typically presents in the epiphyseal region of long bones with a lytic lesion and usually does not have a sclerotic border. It is not typically associated with pain relief by NSAIDs.
- **Option B:** Osteoblastoma - is a rare, benign bone tumor that can present similarly to osteoid osteoma but tends to be larger and more often found in the spine. While it shares some characteristics, the typical presentation and location can help differentiate it.
- **Option D:** Ewing's Sarcoma - is a malignant bone tumor that usually presents with systemic symptoms and a more aggressive radiographic appearance, including permeative bone destruction and often a soft tissue mass. It does not typically present with pain relieved by aspirin.
## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that osteoid osteomas are often diagnosed based on their characteristic pain pattern (nocturnal pain relieved by NSAIDs) and radiographic findings. A classic diagnostic feature is that the pain is typically worse at night and is relieved within 30 minutes to an hour after ingestion of NSAIDs.
## **Correct Answer:** . Osteoid Osteoma
Free Medical MCQs Β· NEET PG Β· USMLE Β· AIIMS
Access thousands of free MCQs, ebooks and daily exams.
By signing in you agree to our Privacy Policy.